Oruka Therapeutics, Inc. Payments to Acquire Available-for-sale Securities
Oruka Therapeutics, Inc. (ORKA) reported Payments to Acquire Available-for-sale Securities of $5.47 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-22.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-11-14
- Oruka Therapeutics, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $0.00.
- Oruka Therapeutics, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $3.43M, a 12.82% increase year-over-year.
- Oruka Therapeutics, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $497.00K, a 95.95% decline year-over-year.
- Oruka Therapeutics, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-03-31 was $1.54M, a 70.35% decline year-over-year.
- Oruka Therapeutics, Inc. payments to acquire available-for-sale securities for fiscal 2017 was $5.47M, a 73.32% decline from fiscal 2016.
- Oruka Therapeutics, Inc. payments to acquire available-for-sale securities for fiscal 2016 was $20.50M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-22 | $3.43M derived: sum of 2 quarters · filed 2018-11-14 | $3.93M derived: sum of 3 quarters · filed 2018-11-14 | $5.47M 10-K · filed 2018-03-22 |
| 2017-09-30 | $3.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $3.93M derived: sum of 2 quarters · filed 2018-11-14 | $5.47M 10-Q · filed 2018-11-14 | $5.47M derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | $497.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $2.04M 10-Q · filed 2018-08-09 | $2.04M derived: sum of 3 quarters · filed 2018-08-09 | $5.08M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $1.54M 10-Q · filed 2018-05-08 | $1.54M derived: sum of 2 quarters · filed 2018-05-08 | $4.58M derived: sum of 3 quarters · filed 2018-05-08 | $16.84M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-22 | $3.04M derived: sum of 2 quarters · filed 2018-03-22 | $15.30M derived: sum of 3 quarters · filed 2018-03-22 | $20.50M 10-K · filed 2018-03-22 |
| 2016-09-30 | $3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $15.30M derived: sum of 2 quarters · filed 2017-11-09 | $20.50M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $12.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $17.46M 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | $5.20M 10-Q · filed 2017-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |